| Bioactivity | DC-Y13-27, a derivative of DC-Y13, is a YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 enhances tumor responses to radiotherapy and immunotherapy[1]. | ||||||||||||
| Name | DC-Y13-27 | ||||||||||||
| Formula | C14H10N2O2S | ||||||||||||
| Molar Mass | 270.31 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Wang L, et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 May 15:S1535-6108(23)00163-0. |